These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 10360370)

  • 21. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
    Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
    Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
    Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
    Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
    Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
    Jehn U; Suciu S; Thomas X; Lefrère F; Muus P; Berneman Z; Marie JP; Adamo F; Fillet G; Nobile F; Ricciuti F; Leone G; Rizzoli V; Montanaro M; Beeldens F; Fazi P; Mandelli F; Willemze R; de Witte T; Amadori S
    Leukemia; 2006 Oct; 20(10):1723-30. PubMed ID: 16932345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
    de Witte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Boogaerts M; Zittoun R; Gratwohl A; Zwierzina H; Hagemeijer A; Willemze R
    Blood; 2001 Oct; 98(8):2326-31. PubMed ID: 11588026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
    Mandelli F; Vignetti M; Suciu S; Stasi R; Petti MC; Meloni G; Muus P; Marmont F; Marie JP; Labar B; Thomas X; Di Raimondo F; Willemze R; Liso V; Ferrara F; Baila L; Fazi P; Zittoun R; Amadori S; de Witte T
    J Clin Oncol; 2009 Nov; 27(32):5397-403. PubMed ID: 19826132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
    Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
    Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
    Van Der Jagt R; Robinson KS; Belch A; Yetisir E; Wells G; Larratt L; Shustik C; Gluck S; Stewart K; Sheridan D;
    Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).
    Lowenthal RM; Bradstock KF; Matthews JP; Bishop JF; Juneja S; Cobcroft R; Eliadis P; Enno A; Gill D; Herrmann RP; Manoharan A; Page FJ; Rooney KF; Rosenfeld D; Seldon M; Taylor KM; Wolf MM; Young GA
    Leuk Lymphoma; 1999 Aug; 34(5-6):501-10. PubMed ID: 10492073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
    Löfgren C; Paul C; Aström M; Hast R; Hedenius M; Lerner R; Liliemark J; Nilsson I; Rödjer S; Simonsson B; Stockelberg D; Tidefelt U; Björkholm M
    Br J Haematol; 2004 Feb; 124(4):474-80. PubMed ID: 14984497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
    Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
    Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
    Harousseau JL; Cahn JY; Pignon B; Witz F; Milpied N; Delain M; Lioure B; Lamy T; Desablens B; Guilhot F; Caillot D; Abgrall JF; Francois S; Briere J; Guyotat D; Casassus P; Audhuy B; Tellier Z; Hurteloup P; Herve P
    Blood; 1997 Oct; 90(8):2978-86. PubMed ID: 9376578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
    Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
    Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous infusion idarubicin and oral busulfan as conditioning for patients with acute myeloid leukemia aged over 60 years undergoing autologous stem cell transplantation.
    Ferrara F; Palmieri S; Annunziata M; Viola A; Pocali B; Califano C; D'Arco AM; Mele G
    Bone Marrow Transplant; 2004 Oct; 34(7):573-6. PubMed ID: 15258559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
    Ferrara F; Melillo L; Montillo M; Leoni F; Pinto A; Mele G; Mirto S
    Ann Hematol; 1999 Aug; 78(8):380-4. PubMed ID: 10460353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
    Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
    Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.